Evidence map›Paper›PMID 42830961›Full record

ArticleiScience2026

Neurofibrillary tangle deposition in primary idiotypic isocortices using flortaucipir PET in histopathologically confirmed Alzheimer's disease.

Keith A Josephs, Stephen D Weigand, Ryota Satoh, Anna Lavrova, Amanda L Tapia, Jonathan Graff-Radford, Mary M Machulda, Kejal Kantarci, Bradley F Boeve, Ronald C Petersen and 6 more

Abstract read
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Keith A JosephsDepartment of Neurology, Mayo Clinic, Rochester, MN 55905, USA.
Stephen D WeigandDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN 55905, USA.
Ryota SatohDepartment of Radiology, Mayo Clinic, Rochester, MN 55905, USA.
Anna LavrovaDepartment of Neurology, Mayo Clinic, Rochester, MN 55905, USA.
Amanda L TapiaDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN 55905, USA.
Jonathan Graff-RadfordDepartment of Neurology, Mayo Clinic, Rochester, MN 55905, USA.
Mary M MachuldaDepartment of Psychiatry and Psychology, Mayo Clinic, Rochester, MN 55905, USA.
Kejal KantarciDepartment of Radiology, Mayo Clinic, Rochester, MN 55905, USA.
Bradley F BoeveDepartment of Neurology, Mayo Clinic, Rochester, MN 55905, USA.
Ronald C PetersenDepartment of Neurology, Mayo Clinic, Rochester, MN 55905, USA.
Clifford R JackDepartment of Radiology, Mayo Clinic, Rochester, MN 55905, USA.
Dennis W DicksonDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.
Aivi T NguyenDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.
R Ross ReichardDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.
Val J LoweDepartment of Radiology, Mayo Clinic, Rochester, MN 55905, USA.
Jennifer L WhitwellDepartment of Radiology, Mayo Clinic, Rochester, MN 55905, USA.

Funding

SUPPLEMENT TO ALZHEIMERS DISEASE PATIENT REGISTRYU01AG006786 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, JACK, CLIFFORD R. · 1986 to 2023
$49.6M
Research Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI Walter K. Kremers · 2019 to 2026
$33.5M
Longitudinal Imaging Biomarkers of Prodromal DLBU01NS100620 · NINDS · MAYO CLINIC ROCHESTER · PI Bradley F Boeve, KEJAL KANTARCI · 2017 to 2026
$19.2M
Disease pathways in the population determined by amyloid, tau, and neurodegeneration imaging biomarkersR37AG011378 · NIA · MAYO CLINIC ROCHESTER · PI CLIFFORD R. JACK · 2018 to 2026
$6.8M
Molecular and structural imaging in atypical Alzheimer's disease: a longitudinal studyR01AG050603 · NIA · MAYO CLINIC ROCHESTER · PI WHITWELL, JENNIFER LOUISE · 2016 to 2025
$5.9M
Flortaucipir PET and histopathology in frontotemporal lobar degeneration and Alzheimer’s diseaseRF1NS112153 · NINDS · MAYO CLINIC ROCHESTER · PI JOSEPHS, KEITH A, WHITWELL, JENNIFER LOUISE · 2021 to 2021
$1.2M
NIA NIH HHS P30 AG062677NIA NIH HHS R01 AG050603NIA NIH HHS R37 AG011378NIA NIH HHS U01 AG006786NINDS NIH HHS RF1 NS112153NINDS NIH HHS U01 NS100620
6 · The paper itself

Abstract

Tau deposition in Alzheimer's disease (AD) spreads throughout the brain in a stereotypical pattern captured by the Braak neurofibrillary tangle staging scheme. While involvement of primary isocortex defines the highest stage, it is unclear whether flortaucipir PET uptake differs among primary isocortical regions. We determined relationships between flortaucipir uptake in primary visual, auditory, motor, and somatosensory isocortices and Braak stage in 155 autopsy-confirmed participants with AD. Flortaucipir uptake was observed starting at Braak stage V, with visual and auditory isocortices showing greater and faster increases in uptake than somatosensory and motor; age and

Indexed as

Alzheimer’s diseasebraak stageflortaucipirisocortexmotor cortextau

Identifiers

PMID42830961
PMCPMC13634365

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.